Patient info Open main menu

Caffeine Citrate 20 mg/ml solution for infusion and oral solution – patient leaflet, side effects, dosage

Last updated: · Text from the MHRA, as of · About this document

Medicine status: Prescription only (POM) Details

Medicine strength:
20 mg/ml
Contains active substance:
ATC code:
Similar medicines:

Patient leaflet - Caffeine Citrate 20 mg/ml solution for infusion and oral solution

1. WHAT CAFFEINE CITRATE 20MG/ML SOLUTION FOR INFUSION AND ORAL

SOLUTION IS AND WHAT IT IS USED FOR

Caffeine citrate 20mg/mL solution for infusion and oral solution contains the active substance caffeine citrate, which is a stimulant of the central nervous system, belonging to a group of medicines called methylxanthines.

Caffeine citrate 20mg/mL solution for infusion and oral solution is used in the treatment of interrupted breathing in premature babies (primary apnoea of premature newborns). These short periods when premature babies stop breathing are due to the baby's breathing centres not being fully developed. This medicine has been shown to reduce the number of episodes of interrupted breathing in premature newborns.

2. WHAT YOU NEED TO KNOW BEFORE YOUR BABY IS GIVEN CAFFEINE CITRATE 20MG/ML SOLUTION FOR INFUSION AND ORAL SOLUTION

Do not use Caffeine citrate 20mg/mL solution for infusion and oral solution:

  • If your newborn is allergic to caffeine citrate or any of the other ingredients of this

    medicine (listed in section 6).

Warnings and precautions

Talk to your baby's doctor before your newborn is given Caffeine citrate 20mg/mL solution for infusion and oral solution.

Prior to starting treatment for apnoea of prematurity with Caffeine citrate 20mg/mL solution for infusion and oral solution other causes of apnoea should have been excluded or properly treated by your baby's doctor.

Caffeine citrate 20mg/mL solution for infusion and oral solution should be used with caution. Please inform your baby's doctor:

  • If your newborn suffers from seizures
  • If your newborn suffers from any heart disease
  • If your newborn has kidney or liver problems
  • If your newborn has frequent regurgitation
  • If your newborn produces more urine than usual
  • If your newborn has a reduced weight gain or food intake
  • If you (the mother) consumed caffeine prior to delivery

Other medicines and Caffeine citrate 20mg/mL solution for infusion and oral solution

Tell your baby's doctor if your newborn is taking, have recently taken or might take any other medicines.

Please inform your baby's doctor if your newborn has been previously treated with theophylline.

Do not use the following medicines during the treatment with Caffeine citrate 20mg/mL solution for infusion and oral solution without talking to your baby's doctor. The doctor may need to adjust the dose or change one of the medicines to something else:

  • theophylline (used to treat breathing difficulties)
  • doxapram (used to treat breathing difficulties)
  • cimetidine (used to treat gastric disease)
  • ketoconazole (used to treat fungine infections)
  • phenobarbital (used to treat epilepsy)
  • phenytoin (used to treat epilepsy)

This medicine may increase the risk for serious intestinal disease with bloody stools (necrotising enterocolitis) when administered with medicines used to treat gastric disease (such as antihistamine H receptor blockers or proton-pump inhibitors that

2

reduces gastric acid secretion).

Pregnancy and breast-feeding

If you (the mother) are breast-feeding while your infant is treated with Caffeine citrate 20mg/mL solution for infusion and oral solution, you should not drink coffee or take any other high caffeine product as caffeine passes into breast milk.

Caffeine citrate 20mg/mL solution for infusion and oral solution contains sodium

This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodium-free'.

3. HOW TO USE CAFFEINE CITRATE 20MG/ML SOLUTION FOR INFUSION AND ORAL SOLUTION

Caffeine citrate 20mg/mL solution for infusion and oral solution should only be used in a neonatal intensive care unit in which adequate facilities are available for patient surveillance and monitoring. Treatment should be initiated under supervision of a physician experienced in neonatal intensive care.

Dose

Your baby's doctor will prescribe the right amount of Caffeine citrate 20mg/mL solution for infusion and oral solution based on your baby's weight. The starting dose is 20 mg per kg body weight (equivalent to 1 mL per kg body weight).

The maintenance dose is 5 mg per kg body weight (equivalent to 0.25 mL per kg body weight) every 24 hours.

Route and method of administration

Caffeine citrate 20mg/mL solution for infusion and oral solution will be infused by controlled intravenous infusion, using a syringe infusion pump or other metered infusion device.

This method is also known as “a drip”.

Some of the doses (maintenance doses) may be given by mouth. It may be needed that your baby's doctor decides to check the levels of caffeine in a blood test

periodically throughout treatment to avoid toxicity.

Duration of treatment

Your baby's doctor will decide exactly how long your newborn must continue therapy with Caffeine citrate 20mg/mL solution for infusion and oral solution. If your baby has 5 to 7 days without apnoea attacks, the doctor will stop the treatment.

If your newborn receives more Caffeine citrate 20mg/mL solution for infusion and oral solution than he/she should

Your newborn may experience fever, rapid breathing (tachypnoea), jitteriness, muscular tremor, vomiting, high blood levels of sugar (hyperglycemia), low blood levels of potassium (hypokalaemia), high blood levels of certain chemicals (urea), elevated number of certain cells (leukocyte) in blood and seizures if he/she receives more caffeine citrate than he/she should.

In the event of this happening treatment with Caffeine citrate 20mg/mL solution for infusion and oral solution should be stopped immediately and your baby's doctor should treat the overdose.

If you have any further questions on the use of this medicinal product, ask your baby's doctor.

4. POSSIBLE SIDE EFFECTS

Like all medicines, this medicine can cause side effects, although not everybody gets them. However, it is difficult to distinguish them from frequent complications occurring in premature babies and complications due to the disease. While under treatment with Caffeine citrate 20mg/mL solution for infusion and oral solution, your newborn may experience some of the following reactions:

Serious side effects

Side effects where the frequency cannot be estimated from the available data - serious intestinal disease with bloody stools (necrotising enterocolitis) The following other side effects may also be considered serious by your baby's doctor in the context of the global clinical evaluation.

Other side effects

Common reported side effects (may affect up to 1 in 10 people)

  • local inflammatory reactions at the infusion site
  • cardiac disorders such as fast heart beat (tachycardia)
  • changes of sugar in blood or serum (hyperglycaemia)

Uncommon reported side effects (may affect up to 1 in 100 people)

  • stimulation of central nervous system such as convulsion
  • cardiac disorders such as irregular heart beat (arrhythmia)

Rare reported side effects (may affect up to 1 in 1,000 people)

  • allergic reactions

Side effects where the frequency cannot be estimated from the available data

  • bloodstream infection (sepsis)
  • changes of sugar in blood or serum (hypoglycaemia), failure to grow, feeding intolerance
  • stimulation of central nervous system such as irritability, nervousness and restlessness; brain injury
  • deafness
  • regurgitation, increase in stomach aspirate
  • increase of urine flow, increase of certain urine components (sodium and calcium)
  • changes in blood tests (reduced levels of haemoglobin after prolonged treatment and reduced thyroid hormone at the start of treatment)

Reporting of side effects

If your newborn gets any side effects, talk to your baby's doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via: United Kingdom: Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google

Play or Apple App Store

Ireland: HPRA Pharmacovigilance Website: www.hpra.ie

By reporting side effects you can help provide more information on the safety of this medicine.

5. HOW TO STORE CAFFEINE CITRATE 20MG/ML SOLUTION FOR INFUSION AND ORAL SOLUTION

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label. The expiry date refers to the last day of that month.

The medicinal product does not require any special storage conditions. Vials of all parenteral solutions must be inspected visually for particulate matter prior to administration.

After opening the vials, the medicinal product should be used immediately.

6. CONTENTS OF THE PACK AND OTHER INFORMATION

What contains

Caffeine citrate 20mg/mL solution for infusion and oral solution

The active substance is caffeine citrate.

Each mL contains 20 mg caffeine citrate (equivalent to 10 mg/mL of caffeine base). Each 3 mL fill in 5mL vial contains 60 mg caffeine citrate (equivalent to 30 mg of caffeine base).

The other ingredients are citric acid monohydrate, sodium citrate dihydrate and water for injections.

What looks like

Caffeine citrate 20mg/mL solution for infusion and oral solution and content of the pack

Caffeine citrate 20mg/mL solution for infusion and oral solution is a solution for infusion and oral solution.

Caffeine citrate 20mg/mL solution for infusion and oral solution is a clear, colourless solution, supplied in glass vial.

It comes in an individual pack of each carton containing 1 vial or in a multipack comprising 5 or 10 individual cartons each containing 1 vial or multipack carton comprising 5 or 10 vials packed using a partition.

Not all pack sizes may be marketed.

Marketing Authorisation Holder

Brown & Burk UK Ltd

Micro House

5 Marryat Close, Hounslow

TW4 5DQ, United Kingdom

Manufacturer (Batch release)

  1. 1)

    Brown & Burk UK Ltd

    Micro House

    5 Marryat Close, Hounslow

    TW4 5DQ, United Kingdom

  2. 2)

    Brown & Burk UK Ltd

    Micro House

    Bury Street, Ruislip

    HA4 7TL, United Kingdom

This leaflet was last revised on 09/2025.

110 mm

BBUK Code

Size: 110(L) x 420(W) mm

Back Side

110 mm

Size: 110(L) x 420(W) mm

Front Side

Caffeine citrate solution for infusion and oral solution - BBUK

20 mg/ml

Leaflet

01

NA

NA

NA

Arial Narrow, 9 pt

110(L) x 420(W) mm

Colours Not for Printing Black

WOA Code No. :

WA

NARevision: 00
Reason for ChangeDate: 05-09-2025
Reviewed byReviewed byReviewed byReviewed by
DepartmentContract Giver/ PL holderRegulatory AffairsHead Production/ Packing (Site)Head QA (Site)
Sign/

Package leaflet: Information for the user Caffeine citrate 20mg/mL solution for infusion and oral solution (equivalent to 10 mg/mL of caffeine base)

3 mm

3 mm

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 25298/0381

Last revision stated in the text: September 2025 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Caffeine Citrate 20 mg/ml solution for infusion and oral solution

Prescription needed? Yes, prescription-only medicine (POM)
Active substance Caffeine citrate
Strength 20 mg/ml
Pharmaceutical form Solution for infusion
Oral solution.
Clear, colourless, aqueous solution at pH=4.7.
How is it taken Oral, Intravenous
Excipients Citric acid monohydrate, Sodium citrate dihydrate, Water for injections
Pack sizes 10 vial
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life 3 years.
After opening the vial, the medicinal product should be used immediately. Chemical and physical compatibility of the diluted solution has been demonstrated for 24 hours at 25°C and at 2-8°C.
From a microbiological point of view, when administered with solutions for infusion the medicinal product should be used immediately after dilution by aseptic technique.
Storage This medicinal product does not require any special storage condition. For storage conditions of the diluted medicinal product see section 6.3.
Drug group (ATC) Psychoanaleptics, xanthine derivatives
  1. N Nervous system drugs
    1. N06 Psychoanaleptics
      1. N06B Psychostimulants, agents used for ADHD and nootropics
        1. N06BC Xanthine derivatives, psychostimulants, agents used for ADHD and nootropics
          1. N06BC01 caffeine
Marketing authorisation PL 25298/0381 (first authorised 22 May 2024)
Marketing authorisation holder Brown & Burk UK Ltd
Codes GTIN 5060124643052 · BNF 04040000

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.2.0 of 19 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.